Science Consulting in Diabe
CEO
Lutz Heinemann studied Process Engineering at the University of Applied Sciences, Düsseldorf, Germany, receiving his degree in 1976, and went on to study Biology at the University of Düsseldorf, qualifying as a Biologist in 1982. After three years as Assistant Professor in the Neurophysiology Department at Düsseldorf University, working with Professor J. Haase, Professor Heinemann transitioned to the field of Internal Medicine. He went on to work with Professor M. Berger at the Clinic for Nutrition and Metabolism in the Centre for Internal Medicine and Neurology from 1985 to 1999. In 1999, Professor Heinemann founded his own company, the Profil Institute for Metabolic Research in Neuss, Germany, where he remained as CEO until 2009. Professor Heinemann is a member of the German Diabetes Association (DDG) and the European Association for the Study of Diabetes (EASD). He also sits on the Scientific Advisory Boards of various pharmaceutical and diagnostics companies. Since 2011, he has been the Managing Editor of the Journal of Diabetes Science and Technology. Professor Heinemann’s scientific research is focused on insulin pharmacology and diabetes technology. Between 2010 and 2015, he acted as coordinator for the EU-funded project AP@home. In 2007 he received an award for “Leadership in Diabetes Technology” from the Diabetes Technology Society and, in 2012, was granted the “Artificial Pancreas Research Award” by the Diabetes Technology Society.

Presenter of 1 Presentation

SIGNIFICANCE AND FUTURE TRENDS OF AID-SYSTEMS FROM THE PERSPECTIVE OF PHYSICIANS

Session Type
Oral Presentations Session
Date
Sat, 30.04.2022
Session Time
11:00 - 12:30
Room
Hall 118
Lecture Time
12:12 - 12:20

Abstract

Background and Aims

How do physicians assess AID-Systems in terms of their current and future importance for diabetes care?

Methods

In 2021 305 diabetologists in Germany (48% female, average age 53.7 years) were asked via online surveys about their current and future assessment of AID-Systems.The results were compared with the 2019 survey, in which 337 diabetologists (43% female, mean age 53.2 years) participated.

Results

Currently, 58.6% (2020: 51.4%) of diabetologists consider AID-Systems to be important for diabetes care, in 5 years 89.3% (2020: 86.4%). Diabetologists estimate that in approx. 9 years one in two PwD TD1 in Germany will be a user of an AID-System, and in approx. 17 years 90% will use an AID-System. Currently, they estimate that 57.6% of all PwD-TD1 are suitable for an AID-System. Diabetologists see the clearest impact of AID-Systems in an increased need for diabetes selfmangement education (78.9%), but also in PwD becoming much more autonomous and empowered (62.8%). Regarding possible negative effects of AID-Systems, diabetologists see only few risks: 20% fear that PWD will have less contact with the diabetes team, 16.9% are concerned that PWD will not be able to cope with the technological change. Only 7.9% fear that PWD will become riskier with AID-Systems, only 1.7% have fears that the diabetes team will become superfluous.

Conclusions

Overall, diabetologists assess AID-Systems as a important innovation for diabetes care and that this will soon become the standard therapy for T1D. The effort for Diabetes self-management education and support is estimated to be relatively high, possible disadvantages relatively low.

Hide